The Efficacy and Safety of Traditional Chinese Medicine (Jiang Zhi Granule) for Nonalcoholic Fatty Liver: A Multicenter, Randomized, Placebo-Controlled Study

Table 2

(a) Primary outcome (L/S ratio) comparison between groups. (b) ANCOVA for mean change in L/S ratio from baseline to end of treatment.

(a)

Follow-ups	FAS			PPS
	JZG	Placebo	𝑃^∗	JZG	Placebo	𝑃
Baseline	0.74±0.21	0.79±0.18	0.0856	0.74±0.21	0.78±0.18	0.1366
Week 12	0.87±0.22	0.82±0.23		0.87±0.22	0.82±0.24
Week 12-baseline	0.13±0.18	0.03±0.17	0.0003	0.13±0.18	0.04±0.18	0.0015
Week 24	0.99±0.24	0.85±0.27		1.00±0.23	0.85±0.28
Week 24-baseline	0.25±0.23	0.06±0.21	0.0011	0.26±0.23	0.07±0.22	0.0003

^∗𝑃 values derived from paired 𝑡-tests for baselines comparison between 2 groups and Wilcoxon signed-rank tests for difference value of L/S ratio from baseline to week 12 and week 24 of treatment.

(b)

	FAS		PPS
	𝐹	𝑃	𝐹	𝑃
Group	38.85	<0.0001	36.19	<0.0001
Baseline	13.69	0.0003	11.35	0.0009
Center	7.25	0.0076	10.15	0.0017
Placebo group* (95% CI)	0.07 (0.03, 0.11)		0.07 (0.03, 0.12)
JZG group* (95% CI)	0.24 (0.20, 0.28)		0.25 (0.21, 0.30)
Mean change between; JZG and placebo group (95% CI)	−0.18 (−0.24, −0.12)		−0.18 (−0.24, −0.12)

∗The values were for mean change in placebo group and mean change in JZG group of the complete treatment, respectively.